The IPO Buzz: Klarna (KLAR) Prices IPO at $40 – $3 Above Range
Klarna Group plc (KLAR), the pioneer in the “Buy Now, Pay Later” space, priced its long-awaited IPO at $40.00 – $3.00 above the top of its range – and sold 34.31 million shares to raise $1.37 billion on Tuesday night, Sept. 9, 2025. At pricing, Klarna had a market cap of about $15.1 billion. Klarna’s IPO price of $40.00 vaulted it above the top of its $35.00-to-$37.00 price range and reflected strong demand for the deal, which had spent years near the top of the IPO market’s “Most Wanted” list.
Klarna’s stock is expected to start trading tomorrow – Wednesday, Sept. 10, 2025 – on the New York Stock Exchange.
Goldman Sachs, J.P. Morgan and Morgan Stanley were the lead joint book-running managers.
BofA Securities, Citigroup, Deutsche Bank Securities, Societe Generale and UBS Investment Bank rounded out the joint book-running team.
Founded in Sweden in 2005, Klarna pioneered the “Pay Later” space when online shopping was in its infancy. That “Pay Later” provision gave consumers the guarantee that they would pay only after they had received the merchandise, according to the prospectus.
In 2018, Klarna launched the Klarna card and the Klarna app (track all of your purchases and shipments in one place).
“In 2019, we strategically decided to expand our successful operating model into additional geographies, with a particular focus on the United States, and in the following three years expanded into 12 additional markets,” Klarna said in the prospectus.
As of June 30, 2025, Klarna served about 111 million “active Klarna consumers” and about 790,000 merchants in 26 countries.
Klarna was in the black for 2024: Klarna reported net income of $21 million on revenue of $2.81 billion for the year that ended Dec. 31, 2024, according to financial statements in the prospectus.
Klarna’s balance sheet slipped back into the red in 2025.
Financial Snapshot: Net loss of $162 million on revenue of $3.01 billion for the 12 months that ended June 30, 2025, according to financial statements in the prospectus.
(For more information about these companies, please check the IPO Calendar and the individual IPO Profiles found on the IPOScoop.com website.)
Note: Never trade on proposed symbols. They have been known to change and you might buy something on the OTC Bulletin Board.
To see what time the NASDAQ IPOs are expected to trade, please log in to: NASDAQTrader.com then scroll down to IPO Message.
Disclosure: Nobody on the IPOScoop.com staff has a position in any stocks mentioned above, nor do they trade or invest in IPOs. The IPOScoop.com staff does not issue advice, recommendations or opinions.
Disclaimer: A SCOOP Rating (Wall Street Consensus of Opening-day Premiums) is a general consensus taken, at press time, from Wall Street and investment professionals concerning how well an IPO might perform when it starts trading. The SCOOP Rating does not reflect the opinions of anyone associated with IPOScoop.com. The SCOOP ratings should not be taken as investment advice. The rating merely reflects the opinion of the professionals at the time of publication and is subject to last-minute changes due to market conditions, changes in a specific offering and other factors, such as changes in the specific offering and other factors, such as changes in the proposed offering terms and the shifting of investor interest in the IPO. The information offered is taken from sources we believe to be reliable, but we cannot guarantee the accuracy.
Source: https://www.iposcoop.com/the-ipo-buzz-klarna-klar-prices-ipo-at-40-3-above-range/
Anyone can join.
Anyone can contribute.
Anyone can become informed about their world.
"United We Stand" Click Here To Create Your Personal Citizen Journalist Account Today, Be Sure To Invite Your Friends.
Before It’s News® is a community of individuals who report on what’s going on around them, from all around the world. Anyone can join. Anyone can contribute. Anyone can become informed about their world. "United We Stand" Click Here To Create Your Personal Citizen Journalist Account Today, Be Sure To Invite Your Friends.
LION'S MANE PRODUCT
Try Our Lion’s Mane WHOLE MIND Nootropic Blend 60 Capsules
Mushrooms are having a moment. One fabulous fungus in particular, lion’s mane, may help improve memory, depression and anxiety symptoms. They are also an excellent source of nutrients that show promise as a therapy for dementia, and other neurodegenerative diseases. If you’re living with anxiety or depression, you may be curious about all the therapy options out there — including the natural ones.Our Lion’s Mane WHOLE MIND Nootropic Blend has been formulated to utilize the potency of Lion’s mane but also include the benefits of four other Highly Beneficial Mushrooms. Synergistically, they work together to Build your health through improving cognitive function and immunity regardless of your age. Our Nootropic not only improves your Cognitive Function and Activates your Immune System, but it benefits growth of Essential Gut Flora, further enhancing your Vitality.
Our Formula includes: Lion’s Mane Mushrooms which Increase Brain Power through nerve growth, lessen anxiety, reduce depression, and improve concentration. Its an excellent adaptogen, promotes sleep and improves immunity. Shiitake Mushrooms which Fight cancer cells and infectious disease, boost the immune system, promotes brain function, and serves as a source of B vitamins. Maitake Mushrooms which regulate blood sugar levels of diabetics, reduce hypertension and boosts the immune system. Reishi Mushrooms which Fight inflammation, liver disease, fatigue, tumor growth and cancer. They Improve skin disorders and soothes digestive problems, stomach ulcers and leaky gut syndrome. Chaga Mushrooms which have anti-aging effects, boost immune function, improve stamina and athletic performance, even act as a natural aphrodisiac, fighting diabetes and improving liver function. Try Our Lion’s Mane WHOLE MIND Nootropic Blend 60 Capsules Today. Be 100% Satisfied or Receive a Full Money Back Guarantee. Order Yours Today by Following This Link.
